Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,762
  • Shares Outstanding, K 2,960
  • Annual Sales, $ 790 K
  • Annual Income, $ -39,480 K
  • 60-Month Beta 1.36
  • Price/Sales 28.65
  • Price/Cash Flow N/A
  • Price/Book 0.98
Trade ONCT with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 55.59%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,340.96% on 10/17/23
  • IV Low 0.00% on 06/26/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 144
  • Open Int (30-Day) 142

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -3.03
  • Number of Estimates 3
  • High Estimate -2.89
  • Low Estimate -3.15
  • Prior Year -3.00
  • Growth Rate Est. (year over year) -1.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.46 +9.17%
on 07/02/24
8.99 -21.58%
on 06/06/24
-2.16 (-23.45%)
since 05/31/24
3-Month
6.46 +9.17%
on 07/02/24
9.88 -28.64%
on 05/28/24
-2.22 (-23.95%)
since 04/02/24
52-Week
5.57 +26.67%
on 01/08/24
13.14 -46.35%
on 12/22/23
+0.15 (+2.17%)
since 06/30/23

Most Recent Stories

More News
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 231.26 (+10.20%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 0.9400 (+8.39%)
AMC : 5.21 (+3.37%)
ONCT : 7.05 (+0.50%)
EVO : 4.95 (+1.85%)
HLN : 8.33 (+0.12%)
CRBG : 29.59 (+1.61%)
Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Transcript

ONCT earnings call for the period ending June 30, 2022.

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 7.05 (+0.50%)
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022

Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27...

ONCT : 7.05 (+0.50%)

Business Summary

Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.02
2nd Resistance Point 8.39
1st Resistance Point 7.72
Last Price 7.05
1st Support Level 6.42
2nd Support Level 5.79
3rd Support Level 5.12

See More

52-Week High 13.14
Fibonacci 61.8% 10.25
Fibonacci 50% 9.35
Fibonacci 38.2% 8.46
Last Price 7.05
52-Week Low 5.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar